This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kurbegov D, Molldrem JJ . Immunity to chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 733–752.
Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657–662.
Maziarz RT . Imatinib mesylate: a novel immune suppressive agent? Blood 2004; 104: 914–915.
Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–2479.
Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.
Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S . Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1099.
Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004; 103: 538–544.
Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005; 105: 1135–1143.
Steegmann JL, Moreno G, Alaez C, Osorio S, Granda A, de la Camara R et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003; 88: 762–768.
Acknowledgements
This study was supported by grants from PAR 2003, MIUR 2003, SIENAIL, Fondazione Monte dei Paschi, EHA clinical research grant 2004. The study was performed after approval by the local ethical committee and informed consent was obtained before patients were entered into the study.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bocchia, M., Abruzzese, E., Forconi, F. et al. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 20, 142–143 (2006). https://doi.org/10.1038/sj.leu.2404029
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404029
This article is cited by
-
Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment
Cancer Immunology, Immunotherapy (2011)
-
Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia
Leukemia (2008)
-
Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia
Leukemia (2007)